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PBMCirus type-1 (HIV-1) Pr55Gag virus-like particles (VLP) represent an interesting HIV
vaccine component since they stimulate strong humoral and cellular immune responses. We demonstrated
that VLP expressed by recombinant baculoviruses activate human PBMC to release pro-inﬂammatory (lL-6,
TNF-α), anti-inﬂammatory (IL-10) and Th1-polarizing (IFN-γ) cytokines as well as GM-CSF and MIP-1α in a
dose-and time-dependent manner. Herein, residual baculoviruses within the VLP preparations showed no or
minor effects. Monocytes could be identiﬁed as a main target for VLP to induce cytokine production.
Furthermore, VLP-induced monocyte activation was shown by upregulation of molecules involved in antigen
presentation (MHC II, CD80, CD86) and cell adhesion (CD54). Exposure of VLP to serum inactivates its capacity
to stimulate cytokine production. In summary, these investigations establish VLP as strong activators of PBMC
and monocytes therein, potently enhancing their functionality and potency to promote an efﬁcient immune
response. This capacity makes VLP an interesting component of combination vaccines.
© 2008 Elsevier Inc. All rights reserved.IntroductionA successful vaccination against human immunodeﬁciency virus
(HIV) depends on an efﬁcient activation of the innate immune
response with the induction of an appropriate cytokine milieu and
enhanced expression of functional surface molecules on antigen-
presenting cells (APC). Despite current progress, the development of a
safe and efﬁcient HIV vaccine is still a major concern and a great
challenge. In the last decade, virus-like particles (VLP) have been
described as being superior to conventional protein immunogens in
the activation of immune responses. For HIV, the Pr55Gag (Gag)
precursor protein has been reported by others and by our group to
include all information allowing for self-assembly into highly
organized lipoprotein particles. These VLP do not replicate, are not
infectious and resemble native immature virions in terms of
morphology and immunogenicity (Gheysen et al., 1989, Vernon et
al., 1991, and Wagner et al., 1992, for review, also see Young and Ross,
2003 and Deml et al., 2005). They can be easily produced in large
quantities by the baculovirus expression system where they are
released from the producer cell by budding (Gheysen et al., 1989,
Royer et al., 1992, and Wagner et al., 1996b). Vaccination with these
VLP induces strong immune responses in mice (Grifﬁths et al., 1993
and Wagner et al. 1996b) and non human primates (Wagner et al.,de (R. Wagner).
l rights reserved.1996a, 1998, Notka et al., 1999 and Paliard et al., 2000), even in
complete absence of additional adjuvants (for review, also see Young
and Ross, 2003, Deml et al., 2005 and Ludwig and Wagner 2007).
However the precise mechanisms of immune activation by VLP are
still not fully understood and yet have been investigated only for
dendritic cells (DCs). Recently, Tsunetsugu-Yokota have provided
evidence that yeast-derived HIV VLP induce DC maturation and
enhanced cytokine production, notably IL-12p70 through the Toll-like
receptor (TLR)-2 signalling pathway (Tsunetsugu-Yokota et al., 2003).
Furthermore Buonaguro et al. reported the maturation and activation
of monocyte-derived DCs by baculovirus-produced Gag VLP through
TLR-2 and-4 independent mechanisms (Buonaguro et al., 2006).
Hereinwe aimed to analyse the capacity of baculovirus-expressed VLP
to stimulate innate immune responses in human PBMC and in
particular to investigate VLP-mediated activation and maturation of
monocytes. Indeed, monocytes are of special relevance for the
initiation of immune responses, since they provide a suitable cytokine
and chemokine environment for attracting immune cells and potent
activation of T cell responses.
In this study, we have demonstrated that VLP possess a strong
capacity to initiate the release of a broad spectrum of pro-and anti-
inﬂammatory cytokines and chemokines from freshly isolated PBMC
in a dose-dependent manner. Furthermore, monocytes considerably
contribute to this VLP effect. In addition, VLP-pulsed monocytes show
a signiﬁcant upregulation of surface molecules playing an important
role in the adhesion to endothelium, in phagocytosis and antigen
47C. Speth et al. / Virology 382 (2008) 46–58presentation. These results strongly support the suitability of VLP for
HIV vaccine purposes.
Results
Production and biochemical characterization of baculovirus-expressed
HIV Gag VLP
Virus-like particles composed of HIV Gag polyprotein (Fig.1A)were
expressed in HighFive™ insect cells. The Gag polyprotein consists of
the functional p17 matrix protein, the p24 capsid protein, the p7
nucleocapsid protein and the late domain-containing protein p6 (Fig.
1A). VLP were puriﬁed from the precleared culture supernatant of Ac-
Gag infectedHighFive™ cells by sequential sedimentation through30%
sucrose cushions and separation of obtained antigens in 10 to 50%
sucrose gradients. Identically puriﬁed antigens from uninfected and
wild-type (wt) baculovirus-infected cells served as controls. Produced
antigens were characterized by Coomassie staining (Fig. 1B) and
immunoblotting (Fig. 1C). Antigenic peak fractions derived from
supernatants of Ac-Gag infected cells included a dominant band with
an apparentmolecularmass of 55 kDa, corresponding to that of theHIV
Gag polyprotein (Figs. 1B and C, lane 3). This band was not visible in
antigen preparations from non infected (lane 1) and wt baculovirus-
infected cells (lane 2). Analysis by Coomassie staining revealed a purity
of producedVLPpreparations of N85% (Fig.1B). Immunoblot analysis of
puriﬁed particles using an anti-Gag antibody conﬁrmed the identity of
Gag protein (Fig. 1C). Electron microscopy showed the presence of
virus-like particles but also residual baculoviruses within the Gag
antigen preparation (Fig. 1D).
VLP induce a variety of immunomodulatory cytokines and chemokines
in human PBMC
The capacity of baculovirus-expressed Gag VLP to modulate innate
immune responses was analyzed in cultures of freshly isolated PBMC.
Incubation of PBMC with VLP triggered the release of the pro-
inﬂammatory cytokines IL-6, TNF-α and IFN-γ (Figs. 2A, C and E).
These cytokines showed substantial differences in their secretion
kinetics: a highly signiﬁcant increase of IL-6 was already measurable
after 6 h and the concentrations in the culture supernatant sub-Fig. 1. Characterisation of Pr55Gag VLP expressed by recombinant baculoviruses in insect c
precursor protein including the p17 matrix (MA), p24 capsid (CA), p7 nucleocapsid (NC) and
cells (lane 1), or cells infected with wild-type baculovirus (lane 2) or with Gag-recombi
sedimentation on sucrose cushions and gradients. Pooled antigenic peak fractions were sepa
using an antibody against the p24 (CA) domainwithin Gag. Arrows at the right indicate the p
Arrows indicate Gag particles (white) and residual baculoviruses (black).sequently remained on a high level for more than 40 h (Fig. 2A).
Elevated amounts of TNF-α were visible with a maximum peak 18 h
after addition of VLP and decreased slightly over time (Fig. 2C),
whereas weak but continuously elevating levels of IFN-γ were
measurable over 70 h post stimulation (Fig. 2E). In addition, varying
concentrations of VLP were necessary to achieve an induction of
different cytokines: signiﬁcant production of IL-6 was observed upon
stimulation with 1.25 μg/ml VLP, whereas 5 μg/ml VLP were required
to stimulate IFN-γ and TNF-α production. The amounts of IL-12
remained below the detection level during the monitored time period
(Fig. 2G).
The participation of residual baculoviruses within the VLP
preparation in the induction of cytokine production was evaluated
in parallel samples. Therefore, PBMC were stimulated with baculo-
viruses at concentrations adequate to that in VLP-pulsed cells (Figs. 2B,
D, F and H). Herein 1 μg VLP included approximately 1.44×106
infectious baculoviruses as determined by a plaque titration assay. A
low contribution of baculovirus to the immunostimulatory effect of
VLP preparations was shown for IL-6 (Fig. 2B) and at late time points
for IFN-γ (Fig. 2F), but not for TNF-α (Fig. 2D).
Similarly, pulsing of PBMC with VLP induced the secretion of the
leukocyte growth factor GM-CSF, anti-inﬂammatory IL-10 and the
chemokine MIP-1α as additional markers of immune activation (Figs.
3C, E and G), whereas the levels of IL-2 remained unaltered (Fig. 3A).
Increased concentrations of these cyto-/chemokines were visible
already after 18 h (GM-CSF and MIP-1α) or 27 h (IL-10), respectively.
The minimal VLP concentration required to achieve enhanced
cytokine and chemokine release was 1.25 μg/ml for the latter three
molecules. Again, stimulation of cells with baculoviruses at concen-
trations corresponding to that in the VLP preparations had no (IL-2,
GM-CSF) or only a minor effects (IL-10) on the production of these
signaling molecules in PBMC (Figs. 3B, D, F and H). Substantially
increased concentrations were only detectable for MIP-1α after 50
and 70 h of stimulation with baculoviruses equivalent to that present
in 12.5 μg/ml of the VLP preparation reaching approximately 50% of
the maximum concentrations observed in VLP-stimulated cells.
These results underline the potent capacity of VLP to induce strong
and rapid cytokine and chemokine responses in human PBMC.
Residual baculoviruses in the VLP preparations did not or only
marginally contribute to this effect.ells and puriﬁed by sucrose density sedimentation. (A) Illustration of the HIV-Pr55Gag
the late domain-containing protein p6 (LI). (B, C) Supernatants of uninfected HighFive™
nant baculovirus (lane 3) were harvested and antigens were puriﬁed by sequential
rated by SDS-PAGE and analyzed by Coomassie staining (B) and by immunoblotting (C)
osition of the Gag protein. (D) Electron microscopic analysis of puriﬁed VLP preparation.
Fig. 2. Expression of pro-inﬂammatory cytokines IL-6 and TNF-α as well as Th1-inducing cytokines IFN-γ and IL-12 in human PBMC after incubationwith VLP. Freshly isolated PBMC
(1×106/ml) were incubated with increasing concentrations of puriﬁed VLP (A, C, E, G) or with baculovirus (B, D, F, H) at concentrations equivalent to those in the corresponding VLP
samples (1.44×106 pfu/μg VLP). Culture supernatants were harvested at indicated time points and the amounts of the cytokines IL-6 (A, B), TNF-α (C, D), IFN-γ (E, F) and IL-12 (G, H)
were quantiﬁed by ELISA. The cytokine levels are presented as mean±SD from three parallel samples.
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Fig. 3. Expression of T cell activating IL-2, anti-inﬂammatory IL-10, immunostimulatory GM-CSF and the chemokine MIP-1α in human PBMC after incubation with VLP. Freshly
isolated PBMC (1×106/ml) were incubated with increasing concentrations of puriﬁed VLP (A, C, E, G) or with baculovirus (B, D, F, H) in concentrations equivalent to those in the
corresponding VLP samples (1.44×106 pfu/μg VLP). Culture supernatants were harvested at indicated time points and the concentrations of IL-2 (A, B), IL-10 (C, D), GM-CSF (E, F) and
MIP-1α (G, H) were quantiﬁed by ELISA. The cytokine levels are presented as mean±SD from three parallel samples.
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50 C. Speth et al. / Virology 382 (2008) 46–58Cellular activity of blood-derived cells in the presence of VLP
or baculoviruses
To conﬁrm the immunostimulatory properties of VLP in cultures of
PBMCweused theMTSassay,which allows for investigationofmetabolic
cell activity (Fig. 4). At concentrations of 5 μg/ml and 12.5 μg/ml VLP
signiﬁcantly enhanced the cellular activity as shown by conversion of the
MTS compound (Fig. 4A). Baculoviruses in concentrations equivalent to
those in the VLP preparation also increased the metabolic activity of the
cells, but the effect was less pronounced (Fig. 4B).
Since monocytes represent an essential subpopulation of antigen-
presenting cells (APC) within the PBMC with relevant capacity to
activate and polarize immune activity we also evaluated the effect of
VLP on this cell type. Again we found a signiﬁcant increase of cellular
activity after incubationwith 5 μg/ml and 12.5 μg/ml VLP as shown by
conversion of the MTS compound (Fig. 4C). Parallel samples incubated
with the equivalent amounts of baculoviruses demonstrated no or
only a minor effect of the residual viruses within the VLP preparation
on the enhancement of the metabolic activity (Fig. 4D).
Cytokine and chemokine production in primary human monocytes
incubated with VLP
Since the MTS experiments implied that monocytes represent a
target of VLP stimulation within PBMC we evaluated the contributionFig. 4. Cellular activity of PBMC and monocytes after incubation with VLP. Freshly isolated hu
increasing concentrations of puriﬁedVLP (A, C) orwith equivalent amounts of baculovirus (1.44×
of the substance by metabolically active cells was measured by ELISA reader. The optical densitof monocytes to the VLP-induced production of cytokines/chemokines
by PBMC. Unlike PBMC, isolated monocytes did not reveal any
signiﬁcant production of IL-6 after stimulation with VLP (Fig. 5A). In
contrast VLP-pulsedmonocytes produced increased levels of TNF-α, IL-
10, GM-CSF and MIP-1α (Figs. 5C, E, G and I). The precise kinetics and
concentrations of released cyto-and chemokines differed from that
observed for PBMC. The corresponding numbers of residual baculo-
viruses had nearly no effect on the production of IL-6, TNF-α and IL-10
(Figs. 5B, D and F). Aminor effect was observed formonocytic synthesis
of GM-CSF (Fig. 5H) and more pronounced MIP-1α (Fig. 5K).
Dose titration experiments with increasing concentrations of
puriﬁed baculoviruses, ranging from 0.025 to 12.5 μg/ml showed,
that even at high concentrations of 12.5 μg/ml baculoviruses do not
induce any release of IL-10 from cultured monocytes after 24 h of
incubation, whereas 2.5 μg/ml VLP were sufﬁcient to induce
signiﬁcant IL-10 production (Fig. 6).
Expression of immunologically relevant maturation molecules on the
surface of VLP-pulsed monocytes
Further experiments aimed to analyse the inﬂuence of VLP on the
expression of monocytic surface molecules which are relevant for the
antimicrobial activity of this cell type. Monocytes were incubated with
increasing concentrations of VLP and the surface expression of the
adhesion molecule CD54 which mediates the monocytic interactionman PBMC (A, B) or monocytes (C, D) derived thereof (1×106/ml) were incubated with
106 pfu/μg VLP) (B, D).MTS reagentwas added at indicated time points and the conversion
y of the staining reaction is presented as mean±SD from three parallel samples.
Fig. 5. Cytokine secretion by monocytes after incubation with VLP. Freshly isolated human monocytes (1×106/ml) were incubated with increasing concentrations of puriﬁed VLP (A,
C, E, G, I) or with equivalent amounts of baculovirus (1.44×106 pfu/mg VLP) (B, D, F, H, K). Culture supernatants were harvested at indicated time points and the amounts of IL-6 (A, B),
IL-10 (C, D), TNF-α (E, F), MIP-1α (G, H) and GM-CSF (I, K) therein were quantiﬁed by ELISA. The cytokine levels are presented as mean±SD from three parallel samples.
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Fig. 6. Role of baculovirus in the VLP-induced IL-10 production. Freshly isolated human
monocytes (1×106/ml) were incubated with medium, 2.5 μg/ml VLP or increasing
concentrations of baculovirus. Culture supernatants were harvested after 24 h and the
amount of IL-10 therein were quantiﬁed by ELISA. The cytokine levels are presented as
mean±SD from three parallel samples.
52 C. Speth et al. / Virology 382 (2008) 46–58with endothelial cells and subsequent penetration into the infected
tissue, was evaluated by FACS. VLP strongly increased the expression of
CD54 compared to medium-treated cells in a dose-dependent manner
(Fig. 7). Even incubation with the lowest concentration of 1 μg/ml
resulted in an increase of themean value from83 to 113.5, and the FACS
mean value of those cells incubatedwith the highest VLP concentration
of 25 μg/ml was 242.4. Similarly, the percentage of cells within an
arbitrary gate increased from 3.4% in the samples with medium to
46.1% in the samples pulsed with 25 μg/ml VLP. Baculoviruses revealed
no effect on the surface signal for CD54 (data not shown).
In parallel experiments the expression of the co-stimulatory
molecules CD80 and CD86 was analysed. The FACS mean value for
CD80 was elevated in a concentration-dependent manner from 13.9 in
medium-treated cells up to 33.2 in cells incubated with 25 μg/ml VLP;
the percentage of cells within an arbitrary gate increased from 2.6% to
32% (Fig. 7). The FACSmeanvalue for CD86was 39.5 for the cells treated
with the highest VLP concentration compared to 15.1 in the medium
control (28.1% of cells within an arbitrary gate versus 6.6%) (Fig. 7).
Again, corresponding amounts of residual baculoviruses did not change
the surface expression of these two molecules (data not shown).
In addition the expression of CD11b, CD18, MHC I and MHC II was
analysed in the presence of 25 μg/ml VLP. Both CD11b and CD18, which
form the heterodimeric complement receptor 3 and thus enable
phagocytic activity, were present in higher amounts on monocytes
incubated with VLP compared to untreated control cells (FACS mean
value 44.5 versus 31.6 for CD11b and 212.9 versus 97.3 for CD18,
respectively; the corresponding percentages of cells within an arbitrary
gatewere 24.2% versus 7.4% for CD11b and 60.9% compared to 12.3% for
CD18) (Fig. 8). An enhanced surface signal was also visible for the
antigen-presenting molecule MHC I (FACS mean value 201.8 in the
presence and 115.5 in the absence of VLP, or 78% compared to 48.7% of
cells within an arbitrary gate) (Fig. 8), whereas the expression ofMHC II
was unaltered (FACS mean value of 213.3 versus 195.3 in the control
sample, or 30.8% versus 28% cells within an arbitrary gate) (Fig. 8).
Corresponding numbers of residual baculoviruses did not change the
surface expression of any of these four molecules (data not shown).
Relevance of the intact VLP structure for their capacity to activate
immune response
We investigated the relevance of the integrity of Gag VLP for their
immunomodulatory characteristics. Whereas addition of VLP to
monocytes resulted in enhanced secretion of IL-10 into the cell culture
supernatant, the disintegration of the particles by the detergent NP-40
completely abolished this effect (Fig. 9A). Similarly the immunomodu-
latory capacity of VLP couldbe largely disruptedby incubation in serum.
Since the serum-induced inactivation of the VLP may be of
particular importance in vivo we analysed the kinetics for this process
in more detail. VLP were still active to induce substantial IL-10
production after incubation in serum for 1 min, but almost completely
failed to induce IL-10 secretion after pre-treatment in serum for 10min
or longer (Fig. 9B). Similarly, pre-incubation of VLP for more than
10 min with serum is required to abolish the upregulation of TNF-α
synthesis (Fig. 9D), whereas a reduced capacity of VLP to stimulate IFN-
γ productionwas observed already after 1min of serum treatment (Fig.
9C). Heat inactivation for 30min at 56 °C largely reversed the inhibitory
effect of serum on the capacity of VLP to stimulate IL-10 production,
indicating the role a heat-labile component (Fig. 9B). Serum did not
disturb the particulate structure of the particles since they showed
unaltered sedimentation in sucrose gradients (data not shown).
Discussion
We and others have previously reported that baculovirus-
expressed HIV Gag virus-like particles (VLP) reveal a strong capacity
to induce T helper-1 (Th-1) cell-mediated humoral and cellularimmune responses in complete absence of any co-administered
immunostimulatory adjuvant (Wagner et al., 1996b, Paliard et al.
2000).
Herein, we show that these VLP per se represent potent activators
of innate immune responses as demonstrated by the induction of
immunomodulatory cytokines such as IFN-γ, TNF-α, IL-6, IL-10 and
GM-CSF and chemokines (MIP-1α) in VLP-pulsed PBMC of HIV-
seronegative blood donors. Moreover, we showed that VLP promote
the activation and maturation of human monocytes, resulting in an
increased secretion of pro (TNF-α)-and anti-inﬂammatory (IL-10)
cytokines in addition the chemokine MIP-1α. VLP-pulsed monocytes
showed substantially enhanced surface expression of CD54 and the
maturation markers CD80, CD86 and MHC II, thus enhancing its
capacity to activate antigen-speciﬁc T cells. Furthermore, VLP-induced
stimulation of GM-CSF production from monocytes and PBMC
promotes in a positive feedback loop the de novo generation of
monocytes and granulocytes from stem cells. The observation that
VLP-pulsed human PBMC and isolated monocytes produce a similar
pattern of cyto- and chemokines indicates a major role of monocytes
in VLP-induced activation of innate immune responses. However,
observed differences in the kinetics and absolute concentrations of
cytokines in cultures of VLP-stimulated PBMC and monocytes as well
as the lack of IL-6 and IFN-γ in VLP-pulsed monocyte cultures strongly
suggest that VLP activate different types of immune cells for cytokine
production. This observation is in accordance with previous ﬁndings
by others, reporting an efﬁcient stimulation of dendritic cells (DC) by
baculovirus-and yeast-derived Gag VLP (Buonaguro et al., 2006,
Tsunetsugu-Yokota et al. 2003). These results show that baculovirus-
expressed VLP support the establishment of an inﬂammatory and Th-
1-polarizing cytokine milieu as well as the activation of APC.
These observations are in accordance with the capacity of VLP to
induce strong Th-1-polarized humoral and cytotoxic T cell responses,
which have been repeatedly demonstrated in VLP-vaccinated mice
and non-human primates (Wagner et al., 1996a, Deml et al., 1997,
Notka et al., 1999, Paliard et al., 2000, Buonaguro, et al., 2002). In
addition, the strong intrinsic Th-1-polarizing adjuvant properties of
VLP may also explain the capacity of VLP to induce enhanced Th-1-
polarized antibody and CTL responses to particle-entrapped and co-
administered synthetic peptides and soluble proteins (Wagner et al.,
53C. Speth et al. / Virology 382 (2008) 46–581996b, 1998, Deml et al., 1997, Buonaguro et al., 2002). Immunoactiva-
tion could be also demonstrated for both PBMC and monocytes as
shown by an increase of the general metabolic activity of the cells. The
reason for the delayed increase in metabolic activity in comparison to
the release of cytokines is unclear. However, one explanation may be,
that it is not directly mediated by VLP, but indirectly by released
cytokines such as GM-CSF.Fig. 7. Effect of increasing concentrations of puriﬁed VLP on surface expression of CD54, CD80
for 3 days at 37 °C with medium or with increasing concentrations of puriﬁed VLP (1 to 25
antibodies (shaded area). As a control, non-speciﬁc binding of immunoglobulin of the sameThe immunostimulatory effects of baculovirus-expressed VLP
resemble that of pathogen-associated molecular patterns (PAMPs)
such as bacterial DNA containing unmethylated CpG-motifs (Sato
et al., 1996 and Klinman et al., 1996) and lipopolysaccharide (LPS).
These bacterial compounds have been described previously to trigger
the activation of inﬂammatory and antimicrobial immune responses
by Toll-like receptor signaling pathways (Hemmi et al., 2000 andand CD86 onmonocytes. Freshly isolated humanmonocytes (1×106/ml) were incubated
μg/ml). The expression of CD54, CD80 and CD86 was monitored by FACS using speciﬁc
isotype was measured (white area).
54 C. Speth et al. / Virology 382 (2008) 46–58Hoshino et al., 1999). It is likely that the VLP preparations include
residual components of the expression system, which may contribute
to the capacity of these complex particulate immunogens to act as a
“danger signal” activating the innate immunity.
Tsunetsugu-Yokota et al. reported that yeast-derived HIV Gag VLP
induce maturation and enhanced cytokine production from dendritic
cells. Internalisation of yeast-derived VLP by both macropinocytosis
and endocytosis came along with the upregulation of CD83 and HLA-
DR and an enhanced production of cytokines, particularly IL-12 and
TNF-α {Tsunetsugu-Yokota et al., 2003}. Herein, yeast cell membranes
were almost equally efﬁcient as yeast-derived VLP regarding the
stimulation of dendritic cell (DC) maturation. In contrast, production
of cytokines by DC was only observed upon stimulation with yeast
cell-derived VLP implicating that besides producer cell-derivedFig. 8. (A) Effect of puriﬁed VLP on the surface expression of CD11, CD18, MHC I andMHC II on
37 °C with medium or with 12.5 μg/ml puriﬁed VLP. The expression of the surface molecules w
binding of immunoglobulin of the same isotype was measured (white area). A typical mono
distribution of monocytes (R1) and lymphocytes (R2).membranes also other particle components may act as “danger
signals” to activate DC by TLR engagement.
Similarly, baculovirus-expressed VLP include insect cell-and
baculovirus-derived impurities such as lipids, nucleic acids and
proteins, some of which have been previously described to support
the activation of innate immune responses. For example, insect and
baculovirus DNA reveal adjuvant activity to stimulate APC (Sun et al.,
1997, Abe et al., 2005). In addition, contaminating baculoviruses and
baculoviral Env proteins, in particular gp64 may also contribute to
the observed immune activation properties of baculovirus-derived
VLP. Herein we showed, that common methods of VLP puriﬁcation
by consecutive separation on sucrose cushions and gradients do not
facilitate complete separation of baculoviruses resulting in traces of
contaminating viruses within the VLP preparations. Baculovirusesmonocytes. Freshly isolated humanmonocytes (1×106/ml) were incubated for 3 days at
as monitored by FACS using speciﬁc antibodies (shaded area). As a control, non-speciﬁc
cyte preparation with approximately 96% purity is shown in (B). The gates indicate the
Fig. 9. Cytokine induction by VLP depending on its particular structure. (A) Freshly isolated human monocytes were incubated either with intact VLP, VLP pre-lysed in the detergent
NP-40 or VLP pre-incubated with human serum. Medium-stimulated cells served as negative controls. Cell culture supernatants were harvested at different time points and the
amount of IL-10 therein was determined by ELISA. The cytokine levels are presented as mean±SD from three parallel samples. (B–D) Puriﬁed VLP (12.5 μg/ml) were given either
directly to freshly isolated monocytes or were pre-incubated with serum for different time periods ranging from 1min to 2 h. For one set of samples the serumwas heated for 30 min
at 56 °C before addition of the VLP for further 30 min. Monocytes incubated only with medium or with serum in the absence of VLP served as negative controls. Cell culture
supernatants were harvested after 16 h of incubation and IL-10 (B), IFN-γ (C) and TNF-α (D) were quantiﬁed by ELISA. Each bar represents the mean±SD from three parallel samples.
55C. Speth et al. / Virology 382 (2008) 46–58represent potent inductors of innate cytokine production in murine
and human cells (Gronowski et al., 1999, Abe et al., 2003, 2005).
Accordingly, gp64-mediated uptake of baculoviruses and interaction
of released baculoviral DNA with TLR 9 within endosomal compart-
ments has been suggested to be necessary for the activation of
innate immune responses (Abe et al., 2005). We speculate that
baculovirus-expressed VLP may stimulate innate immune responses
by a similar mechanism as described for baculoviruses. Thishypothesis is based on our observation, that VLP produced in the
baculovirus system include high concentrations of the fusogenic
baculovirus protein gp64. However, this hypothesis remains to be
conﬁrmed in future experiments.
In addition, we showed that disruption of VLP by the detergent NP-
40 and incubationwith human serum including active components of
the complement substantially impedes the capacity of VLP to
stimulate cytokine secretion as shown for IL-10, IFN-γ and TNF-α.
56 C. Speth et al. / Virology 382 (2008) 46–58The observation, that heat inactivated serum did not signiﬁcantly alter
implies a putative role of complement in particle disintegration since
this temperature is typically used to inactivate the complement
components. Unlike NP-40 treatment, perforation of VLP with
complement did not signiﬁcantly alter the sedimentation behavior
in sucrose gradients (data not shown) indicating an unaltered
particulate structure of complement-treated Gag VLP. However, both
treatments may induce the release of nucleic acids from the particles,
thus affecting its potency to activate cells of the innate immune
system. These observations underline the importance of the particu-
late structure and composition of these complex antigens for its
efﬁcacy to activate innate immunity.
In contrast, we showed, that the residual baculoviruses within the
VLP preparations contributed only to a minor extent to the
immunostimulatory properties of baculovirus-expressed VLP since
they induced only low levels of IL-6, IFN-γ and IL-10 in addition to a
signiﬁcant production of MIP-1α from human PBMC as well as poor
concentrations of IL-6, IL-10 GM-CSF and MIP-1α from monocytes.
In summary, this study emphasizes the strong capacity of
baculovirus-expressed VLP to stimulate innate immunity as a
prerequisite for the induction of cell-mediated immune responses. A
more detailed understanding of structural characteristics of VLP and
the role of producer cell-derived components in the activation and
polarization of innate immunity will lead to a rational improvement of
the immunogenicity of VLP antigens for HIV vaccine purposes.
Materials and methods
Monoclonal antibodies
The monoclonal antibodies (mab) 16/4/2 and 13-5 have been
previously mapped within the p24 (CA) moiety of the HIV Gag
polyprotein (Wolf et al., 2008). The capture and detection antibodies
for ELISA recognizing IL-2, IL-6, IL-10, IL-12, TNF-α and GM-CSF were
purchased from Pharmingen/Becton Dickinson (Franklin Lakes, USA);
antibodies for the quantiﬁcation of IFN-γ and MIP-1α were obtained
from R&D Systems (McKinley Place, USA). The antibodies utilized for
the detection of CD54, CD80 and CD86 by ﬂow cytometry were
obtained from Pharmingen/Becton Dickinson and the IgG control
antibody was purchased from Dako (Hamburg, Germany).
Media, cells and viruses
Recombinant baculoviruses expressing the full-length HIV-1
Pr55Gag (Gag) polyprotein (Ac-Gag) were constructed and propagated
as previously described in detail (Wagner et al., 1996b, Smith et al.,
1985). For large scale preparation of recombinant virus-like particles
(VLP), HighFive™ insect cells derived from Trichoplusia ni egg cell
homogenates (Invitrogen Inc., San Diego, USA) were used for infection
with recombinant baculoviruses.
Sf9 cells were maintained in TC100 medium (Gibco BRL, Eggen-
stein, Germany) supplemented with 10% fetal calf serum (FCS), 100 IU
of penicillin per ml and 100 μg of streptomycin per ml. HighFive™ cells
were propagated in serum-free Insect-Xpress medium (Cambrex,
Walkersville, MD) supplemented with 100 μg/ml kanamycin sulfate
(PAN, Oberasbach, Germany). All insect cell-lines were maintained at
24 to 27 °C.
Puriﬁcation and biochemical characterization of VLP
HIV-1 Gag virus-like particles (VLP) were produced using the
baculovirus expression system as described previously in detail
(Wagner et al., 1996b). In brief, VLP were expressed by infection of
HighFive™ cells with the recombinant baculovirus Ac-Gag at a
multiplicity of infection (m.o.i.) of 10. After 3 days of infection VLP
were pelleted from precleared cell culture supernatants (2000 ×g , for10 min at 4 °C) by sedimentation through a 30% sucrose cushion at
100,000 ×g for 2.5 h at 16 °C. Pelleted antigen was allowed to
resuspend overnight in PBS, pH 7.5 and VLP were further puriﬁed by
separation on 10–50% sucrose gradients and subsequent dialysis of
combined antigenic peak fractions against PBS (Wagner et al., 1994).
Analysis of pooled antigenic peak fractions of VLP was performed by
separation on a 12.5% denaturing sodium-dodecyl sulfate (SDS)
polyacrylamide gel followed by Coomassie staining. The identity of
the produced particles was veriﬁed by immunoblotting. For that
purpose proteins were transferred from SDS gels to nitrocellulose
membranes (Millipore, Bedford, MA01730, USA) by electroblotting in a
transfer buffer (25 mM Tris, 190 mM glycine, 20% methanol). The Gag
polyprotein was labeled speciﬁcally by sequential incubation with a
1:2000 dilution of the HIV-1 p24-speciﬁc monoclonal antibody 13-5
(Wolf et al. 2008) and a 1:1000 dilution of an alkaline phosphate-
labeled goat anti-mouse immunoglobulin G (Bio-Rad Laboratories,
Munich, Germany). Proteins were visualized using a NBT/BCIP solution
(0.3% 4-nitro-blue-tetrazolium-chloride (NBT), 0.3% 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP), 100 mM Tris, 100 mM NaCl,
50 mM MgCl2, pH 9.5). Yields of produced VLP were calculated using
a Biorad protein assay (Bio-Rad Laboratories, München, Germany).
Electron microscopy
Supernatants of Ac-Gag-infected High Five™ cells were clariﬁed by
centrifugation at 500 ×g for 10 min at 4 °C and then centrifuged
through 30% (w/v) sucrose cushions for 2.5 h at 100,000 ×g and 16 °C.
The pelleted antigens were dissolved in PBS without bivalent ions and
centrifuged on 10 to 50% (w/v) sucrose gradients at 100,000 ×g for 16 h
at 4 °C followed by fractionation. Gag-rich fractions were subjected to
electron microscopic analysis. Therefore, the sample suspension was
shaken gently, approximately 30 μl drops were retrieved and placed
on clean paraﬁlm sheets. Formvar-and carbon-coated positively glow-
discharge treated cupper grids were incubated on the top of the
suspension droplets for 10 min and subsequently blotted dry with a
ﬁlter paper. After a washing step of 15 s on a droplet of aqua bidest.,
the grids were blotted again and air-dried for 10 min. Subsequently,
each sample was negative stained with 2% aqueous phosphotungstic
acid (pH 7.2) for 1 min using the droplet technique and air-dried for at
least 30 min. The samples were examined in a LEO912AB electron
microscope (Zeiss, Oberkochen/Germany) operating at 80 kV,
equipped with a bottom-mounted CCD-camera capable of recording
images with 1 k×1 k pixels. The documentation was done with the
iTEM-software, Ver. 5.0 (Olympus Soft Imaging Solutions GmbH,
Muenster/Germany).
Titration of baculoviruses by plaque assay
A plaque assay in a 6-well plate format was used to determine the
titer of baculoviruses. Therefore 2×106 Sf9 cells were seeded in each
well of two Multiwell™ 6-well plates (Falcon, Becton Dickinson
Labware) and allowed to settle down at the bottom of the plates
during 2 h of cultivation at 25 °C. Cells were infected with serial 10-
fold dilutions of test samples and incubated for 30 min at 25 °C on a
rocking plate. Then, medium was replaced with 2 ml plaquing
medium (40% TC 100 2× medium, 10% FCS, 1% PenStrep, and 50% of
3% (w/w) soft agar). Then, cells were incubated for 3 days at 25–27 °C,
and a neutral red agarose overlay (40% TC 100 2x medium,10% FCS, 6%
neutral red solution (2 g neutral red, 250 ml of 75% ethanol), 1%
PenStrep, and 50% of 1.8% (w/w) softagar was added to eachwell. Then
cells were incubated for additional 7–9 days until plaques became
visible. The viral titer was calculated by multiplying the number of
plaques by the dilution factor and was indicated as plaque-forming-
units (pfu) per ug VLP. Freshly produced Gag-particles included
approximately 1.44×106 infectious baculoviruses (pfu)/μg VLP, as
determined by plaque titration.
57C. Speth et al. / Virology 382 (2008) 46–58Isolation of monocytes from human blood and determination of cellular
activity by an MTS assay
Buffy-coats were obtained by centrifuging whole blood samples
from healthy, HIV-seronegative donors for 15 min at 430 ×g and room
temperature with the brake off. Human PBMC were isolated from
buffy-coats by density gradient centrifugation using Biocoll (Bio-
chrom, Berlin) and cultivated in complete RPMI medium (Invitrogen,
Carlsbad, USA) containing 10% heat inactivated FCS (Sigma, St. Louis)
and 2 mM L-glutamine (Invitrogen) at 37 °C in a humidiﬁed 5% CO2
atmosphere. To isolate monocytes, Petri dishes were coated with
sterile 2% gelatine solution (Merck, Darmstadt) for 2 h at 37 °C
followed by incubation with autologous plasma for 30 min at 37 °C.
PBMC were loaded onto gelatine/plasma-coated plates at 4×106 cells/
ml. After 40 min of incubation at 37 °C peripheral blood lymphocytes
(PBL) were washed out with medium and the adherent monocytes
were detached with 5 mM EDTA (Invitrogen) and further cultured in
complete RPMI medium. Fluorescence-activated cell sorter (FACS)
analysis revealed that the obtained cell population regularly consisted
of 96–98% monocytes (see Fig. 8B).
The mitochondrial activity of cells was analysed using a commer-
cially available test kit according to the manufacturer's instruction
(Promega, Madison, USA). Brieﬂy, PBMC or monocytes were incubated
either with VLP or the corresponding amounts of baculoviruses, which
are present in VLP-pulsed cells. At indicated time points 3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophe-
nyl)-2 H tetrazolium (MTS) was added to the cells and the conversion
of the substance by active mitochondrial enzymeswasmeasured in an
ELISA reader by determining the optical density (OD) at dual
wavelengths of 492 nm to 620 nm.
Determination of cytokine expression by VLP-pulsed cells
PBMC or monocytes were seeded at 1×106 cells/ml in RPMI 1640
medium containing 10% FCS, 1% penicillin-streptomycin (Invitrogen)
and cultured in presence or absence of various VLP concentrations. As
control, cells were incubated with baculovirus at concentrations
corresponding to that in the VLP preparations. For some experiments,
cells were incubatedwith VLP, which had been pre-treated with a 1:10
dilution of normal human serum (NHS), followed by addition of
18 mM EDTA.
Cell-free culture supernatants were collected and the content
of individual cytokines was tested by ELISA. Therefore, ELISA
plates were coated overnight at 4 °C with 2 μg/ml capture antibody
followed by washing with PBS/0.1%Tween-20 and incubation
with culture supernatants for 1 h at room temperature. After
subsequent washing the biotinylated detection antibody was
added for 1 h at a concentration of 500 ng/ml. After 3 washings,
the plates were incubated for 1 h at 37 °C with avidin-horseradish
peroxidase conjugate (DAKO, Vienna). After 4 ﬁnal washes, the
plates were developed with tetramethylbenzidine dihydrochloride
(Sigma) for 5 min. The reaction was stopped with 2 M H2SO4, and
the optical density (OD) was measured at dual wavelengths of 450
to 620 nm.
FACS analysis of surface molecule expression
After the appropriate incubation time, antigen-pulsed cells were
pre-treated with 0.5% trypsin/0.2% EDTA for 10 min to detach
adherent cells and were washed twice with PBS/0.5% BSA. To
measure cell surface expression of proteins, cells were incubated
with 5 μg/ml of the appropriate speciﬁc antibody or unspeciﬁc IgG as
isotype control for 30 min at 4 °C, washed again with PBS/BSA and
then stained with a second FITC-labeled antibody (DAKO). Analyses
were performed using a FACScan ﬂow cytometer (Becton Dickinson,
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